University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Adil Daud, MD

Adil Daud, MD

HS Clinical Professor, Department of Medicine (Hematology/Oncology), UCSF; Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center

Cancer Center Program Memberships

Cancer Immunology

Education

St. Francis De Sales College, Nagpur, India, 1980, HSC diploma in general science
Government Medical College, Nagpur, India, 1986, MBBS degree in Medicine


Professional Experience

  • 1987-1990
    Postdoctoral Fellow, Laboratory of F. Merlin Bumpus, PhD and Ahsan Husain, PhD, Cleveland Clinic Foundation, Cleveland, OH
  • 1990-1994
    Research Assistant Staff, Laboratory of Loren Field, PhD, Krannert Institute of Cardiology, Indiana University Medical Center, Indianapolis, IN
  • 1994-1997
    Internship and Residency in Internal Medicine, Indiana University Medical Center, Indianapolis, IN
  • 1997-2000
    Fellowship in Hematology/Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
  • 2000-2001
    Clinical Attending Physician, Developmental Chemotherapy, Memorial Sloan-Kettering Cancer Center, New York, NY
  • 2001-2005
    Assistant Professor, Cutaneous Oncology and GI Comprehensive Program, H. Lee Moffitt Cancer Center, Tampa, FL
  • 2006-2008
    Associate Professor, Cutaneous Oncology, GI and Experimental Therapeutics Program, H Lee Moffitt Cancer Center, Tampa, FL
  • 2006-2008
    Director, Moffitt Clinical Research Network
  • 2008-2010
    Clinical Associate Professor and Director, Melanoma Clinical Research, University of California, San Francisco, CA
  • 2010-present
    HS Clinical Professor of Medicine and Director, Melanoma Program, University of California, San Francisco, San Francisco CA

Honors & Awards

  • 1986
    Honors in Pediatrics, Government Medical College, Nagpur, India
  • 2000
    Young Investigator Award, American Society for Clinical Oncology for project “Regulation of mRNA stability by Elongation factor I.
  • 2005-2007
    Clinical Trial Award: Highest Number of Patients Enrolled in clinical trials at Moffitt Cancer Center
  • 2007-2010
    Best Doctors in America Award, Castle Connolly

Selected Publications

  1. Binnewies M, Mujal AM, Pollack JL, Combes AJ, Hardison EA, Barry KC, Tsui J, Ruhland MK, Kersten K, Abushawish MA, Spasic M, Giurintano JP, Chan V, Daud AI, Ha P, Ye CJ, Roberts EW, Krummel MF. Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity. Cell. 2019 Mar 12.
    View on PubMed
  2. Algazi AP, Rotow J, Posch C, Ortiz-Urda S, Pelayo A, Munster PN, Daud A. A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma. Pigment Cell Melanoma Res. 2019 Feb 24.
    View on PubMed
  3. Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker AI, Burgess MA, Hanks BA, Olencki T, Margolin K, Lundgren LM, Soni A, Ramchurren N, Church C, Park SY, Shinohara MM, Salim B, Taube JM, Bird SR, Ibrahim N, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. J Clin Oncol. 2019 Mar 20; 37(9):693-702.
    View on PubMed
  4. Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L. Clonal Deletion of Tumor-Specific T Cells by Interferon-? Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. Immunity. 2019 Feb 01.
    View on PubMed
  5. Bridge JA, Lee JC, Daud A, Wells JW, Bluestone JA. Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. Front Med (Lausanne). 2018; 5:351.
    View on PubMed
  6. Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, Daud AI, Pai SI, Zippelius A, Weissleder R, Pittet MJ. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-? and IL-12. Immunity. 2018 Dec 18; 49(6):1148-1161.e7.
    View on PubMed
  7. Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC. Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clin Cancer Res. 2018 Dec 01; 24(23):6098.
    View on PubMed
  8. Hamid O, Robert C, Ribas A, Hodi FS, Walpole E, Daud A, Arance AS, Brown E, Hoeller C, Mortier L, Schachter J, Long J, Ebbinghaus S, Ibrahim N, Butler M. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer. 2018 Sep; 119(6):670-674.
    View on PubMed
  9. Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. Eur J Cancer. 2018 Sep; 101:236-243.
    View on PubMed
  10. Sanlorenzo M, Vujic I, Esteve-Puig R, Lai K, Vujic M, Lin K, Posch C, Dimon M, Moy A, Zekhtser M, Johnston K, Gho D, Ho W, Gajjala A, Oses Prieto J, Burlingame A, Daud A, Rappersberger K, Ortiz-Urda S. The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma. Sci Rep. 2018 Jul 19; 8(1):10902.
    View on PubMed
  11. Johnson DB, Bordeaux J, Kim JY, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy J, Witte JS, McKee SB, Ko J, Wrangle JM, Dabbas B, Tangri S, Lameh J, Hall J, Markowitz J, Balko JM, Dakappagari N. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. Clin Cancer Res. 2018 Nov 01; 24(21):5250-5260.
    View on PubMed
  12. Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, Alvarado MD, Wolf DM, Bogunovic D, Bhardwaj N, Daud AI, Ha PK, Ryan WR, Pollack JL, Samad B, Asthana S, Chan V, Krummel MF. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018 Aug; 24(8):1178-1191.
    View on PubMed
  13. Daud AI. Negative but not futile: MAGE-A3 immunotherapeutic for melanoma. Lancet Oncol. 2018 Jul; 19(7):852-853.
    View on PubMed
  14. Cuevas LM, Daud AI. Immunotherapy for melanoma. Semin Cutan Med Surg. 2018 Jun; 37(2):127-131.
    View on PubMed
  15. Daud AI. Melanocytic Neoplasms, Introduction. Semin Cutan Med Surg. 2018 Jun; 37(2):87.
    View on PubMed
  16. Xu MJ, Wu S, Daud AI, Yu SS, Yom SS. In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series. J Immunother Cancer. 2018 May 30; 6(1):43.
    View on PubMed
  17. Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clin Cancer Res. 2018 Oct 15; 24(20):4960-4967.
    View on PubMed
  18. Humphries A, Daud A. The gut microbiota and immune checkpoint inhibitors. Hum Vaccin Immunother. 2018; 14(9):2178-2182.
    View on PubMed
  19. Daud AI. Revisiting RECIST: the case of treatment beyond progression. Lancet Oncol. 2018 02; 19(2):157-159.
    View on PubMed
  20. Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol. 2018 Jun 10; 36(17):1668-1674.
    View on PubMed

Go to UCSF Profiles, powered by CTSI